United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz Sells 10,000 Shares

Posted by Matthew Tipps on Feb 5th, 2025

United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $353.64, for a total transaction of $3,536,400.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $911,330.28. This represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Michael Benkowitz also recently made the following trade(s):

On Monday, January 27th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $370.71, for a total transaction of $3,707,100.00.
On Tuesday, January 21st, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $364.91, for a total transaction of $3,649,100.00.
On Monday, January 13th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $364.62, for a total transaction of $3,646,200.00.
On Monday, December 30th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $356.68, for a total transaction of $3,566,800.00.
On Monday, December 23rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $361.95, for a total transaction of $3,619,500.00.
On Monday, November 25th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $372.75, for a total value of $3,727,500.00.
On Monday, November 11th, Michael Benkowitz sold 15,000 shares of United Therapeutics stock. The shares were sold at an average price of $407.32, for a total value of $6,109,800.00.
On Thursday, November 7th, Michael Benkowitz sold 15,000 shares of United Therapeutics stock. The stock was sold at an average price of $401.44, for a total transaction of $6,021,600.00.

United Therapeutics Price Performance

NASDAQ UTHR opened at $353.43 on Wednesday. The company has a market capitalization of $15.78 billion, a P/E ratio of 15.52, a PEG ratio of 0.92 and a beta of 0.57. The company’s 50 day simple moving average is $364.28 and its 200 day simple moving average is $357.68. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $417.82.

Analyst Ratings Changes

Several equities analysts have issued reports on UTHR shares. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 16th. HC Wainwright increased their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. LADENBURG THALM/SH SH raised their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. The Goldman Sachs Group increased their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a report on Friday, November 1st. Finally, Argus upped their target price on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $378.36.

Read Our Latest Research Report on UTHR

Institutional Investors Weigh In On United Therapeutics

Hedge funds have recently made changes to their positions in the company. World Investment Advisors LLC acquired a new stake in United Therapeutics during the 3rd quarter worth about $139,206,000. FMR LLC grew its stake in shares of United Therapeutics by 41.1% in the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock valued at $386,168,000 after buying an additional 314,004 shares in the last quarter. AustralianSuper Pty Ltd increased its holdings in United Therapeutics by 577.1% in the fourth quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company’s stock worth $66,962,000 after buying an additional 161,751 shares during the last quarter. Assetmark Inc. raised its position in United Therapeutics by 56.9% during the third quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock valued at $150,492,000 after acquiring an additional 152,249 shares in the last quarter. Finally, Franklin Resources Inc. lifted its stake in United Therapeutics by 97.7% in the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock valued at $89,532,000 after acquiring an additional 123,929 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.